Aliases & Classifications for Inverted Papilloma

MalaCards integrated aliases for Inverted Papilloma:

Name: Inverted Papilloma 12 15 73
Inverted Papilloma, Squamous Cell 12
Inverted Squamous Cell Papilloma 73
Papilloma, Inverted 44
Papilloma Inverted 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3179
MeSH 44 D018308
NCIt 50 C3793
SNOMED-CT 68 104081000119103

Summaries for Inverted Papilloma

MalaCards based summary : Inverted Papilloma, also known as inverted papilloma, squamous cell, is related to urinary tract papillary transitional cell benign neoplasm and inverted transitional papilloma. An important gene associated with Inverted Papilloma is KRT13 (Keratin 13), and among its related pathways/superpathways are Cell cycle and DNA Damage. The drugs Fentanyl and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and liver.

Wikipedia : 76 An inverted papilloma is a type of tumor in which surface epithelial cells grow downward into the... more...

Related Diseases for Inverted Papilloma

Diseases related to Inverted Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 urinary tract papillary transitional cell benign neoplasm 33.2 KRT20 TP53
2 inverted transitional papilloma 32.6 CDKN2A KRT7
3 schneiderian carcinoma 30.8 CDKN2A TP53
4 larynx cancer 30.3 CDKN2A MKI67 TP53
5 squamous cell carcinoma 30.0 CDKN2A MKI67 SERPINB3 TP53
6 papillary adenocarcinoma 30.0 KRT7 TP53
7 bladder urothelial carcinoma 29.8 KRT20 KRT7 TP53
8 transitional cell carcinoma 29.7 CDKN2A KRT20 KRT7 TP53
9 papilloma 29.3 CDKN2A KRT13 KRT20 KRT7 PCNA TP53
10 basaloid squamous cell carcinoma 29.1 CDKN2A KRT13 KRT7 TP53
11 ureter inverted papilloma 12.3
12 frontal sinus inverted papilloma 12.3
13 maxillary sinus inverted papilloma 12.3
14 sphenoid sinus inverted papilloma 12.3
15 nasal cavity inverting papilloma 12.2
16 urinary bladder inverted papilloma 12.2
17 renal pelvis inverted papilloma 12.1
18 ethmoid sinus inverted papilloma 12.1
19 urethra inverted papilloma 12.1
20 brain ependymoma 10.9 MKI67 TP53
21 brain stem astrocytic neoplasm 10.8 CDKN2A TP53
22 ameloblastic carcinoma 10.8 CDKN2A MKI67
23 endometrial mucinous adenocarcinoma 10.8 CDKN2A MKI67
24 keratinizing squamous cell carcinoma 10.8 CDKN2A TP53
25 bartholin's gland benign neoplasm 10.8 CDKN2A TP53
26 thyroid lymphoma 10.7 CDKN2A TP53
27 adenosarcoma 10.7 MKI67 TP53
28 bone squamous cell carcinoma 10.7 CDKN2A TP53
29 scrotal carcinoma 10.7 CDKN2A TP53
30 anal squamous cell carcinoma 10.7 CDKN2A TP53
31 soft tissue sarcoma 10.7 MKI67 TP53
32 gastric adenosquamous carcinoma 10.7 CDKN2A TP53
33 anogenital venereal wart 10.7 CDKN2A TP53
34 megaesophagus 10.7 CDKN2A TP53
35 cervix uteri carcinoma in situ 10.7 CDKN2A TP53
36 meningeal melanomatosis 10.7 CDKN2A TP53
37 dedifferentiated liposarcoma 10.7 CDKN2A TP53
38 oropharynx cancer 10.7 CDKN2A TP53
39 embryonal sarcoma 10.7 MKI67 TP53
40 lymphoid interstitial pneumonia 10.6 KRT13 TP53
41 cervix small cell carcinoma 10.6 CDKN2A TP53
42 optic nerve neoplasm 10.6 CDKN2A TP53
43 sinusitis 10.6
44 keratocystic odontogenic tumor 10.6 MKI67 TP53
45 recessive dystrophic epidermolysis bullosa 10.6 CDKN2A TP53
46 bladder papillary transitional cell neoplasm 10.6 KRT20 TP53
47 squamous cell papilloma 10.5 CDKN2A TP53
48 bizarre leiomyoma 10.5 CDKN2A PCNA
49 testicular torsion 10.5 PCNA TP53
50 mature teratoma 10.5 PCNA TP53

Graphical network of the top 20 diseases related to Inverted Papilloma:



Diseases related to Inverted Papilloma

Symptoms & Phenotypes for Inverted Papilloma

Drugs & Therapeutics for Inverted Papilloma

Drugs for Inverted Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
4
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
9 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
10 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Infective Agents Phase 2, Phase 3,Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
13 Adjuvants, Anesthesia Phase 3
14 Analgesics Phase 3
15 Analgesics, Opioid Phase 3
16 Anesthetics Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Central Nervous System Depressants Phase 3
20 Narcotics Phase 3
21 Peripheral Nervous System Agents Phase 3,Not Applicable
22 Antifungal Agents Phase 2, Phase 3,Phase 1
23 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
24 Hormone Antagonists Phase 2, Phase 3
25 Hormones Phase 2, Phase 3,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
27 Steroid Synthesis Inhibitors Phase 2, Phase 3
28 Autonomic Agents Phase 3,Not Applicable
29 Cholinergic Agents Phase 3,Not Applicable
30 Neurotransmitter Agents Phase 3,Not Applicable
31 Antineoplastic Agents, Hormonal Phase 3
32 Appetite Stimulants Phase 3
33 Central Nervous System Stimulants Phase 3,Not Applicable
34 Contraceptive Agents Phase 3
35 Contraceptives, Oral Phase 3
36
Megestrol Phase 3 3562-63-8 19090 3080587
37 Antidepressive Agents Phase 3
38 Antidepressive Agents, Tricyclic Phase 3
39 Histamine Antagonists Phase 3
40
Histamine Phosphate Phase 3 51-74-1 65513
41 Psychotropic Drugs Phase 3
42 Antimitotic Agents Phase 3,Phase 2,Phase 1
43 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
47
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
48
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
49
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
50
Etoposide Approved Phase 2 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
8 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
9 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
10 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
11 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
12 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
13 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
14 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
15 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
16 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
17 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
18 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
19 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
20 Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer Unknown status NCT00896350 Phase 1 chemotherapy
21 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
22 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
23 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
24 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
25 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
26 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
27 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
28 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
29 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
30 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
31 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
32 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
33 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
34 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
35 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
36 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
37 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
38 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
39 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1 HPPH;photodynamic therapy
40 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
41 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
42 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074
43 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 Not Applicable cyclophosphamide
44 Squamous Cell Carcinoma Antigen Analysis at the University Hospital Ostrava Completed NCT01827423 Not Applicable
45 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
46 Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00973947 Not Applicable
47 Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer Completed NCT00898300
48 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
49 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896
50 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336

Search NIH Clinical Center for Inverted Papilloma

Cochrane evidence based reviews: papilloma, inverted

Genetic Tests for Inverted Papilloma

Anatomical Context for Inverted Papilloma

MalaCards organs/tissues related to Inverted Papilloma:

41
Lung, Brain, Liver, Skin, Bone, Breast, Kidney

Publications for Inverted Papilloma

Articles related to Inverted Papilloma:

(show top 50) (show all 598)
# Title Authors Year
1
Clinical features of nasal and sinonasal inverted papilloma associated with malignancy. ( 29548524 )
2018
2
Better surgical outcome by image-guided navigation system in endoscopic removal of sinonasal inverted papilloma. ( 29678350 )
2018
3
Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing. ( 29779136 )
2018
4
Management of Inverted Papilloma During Holmium Laser Enucleation of the Prostate. ( 29545053 )
2018
5
Optical coherence tomography and confocal laser scanning microscopy as non-invasive tools in the diagnosis of sinonasal inverted papilloma: a pilot study. ( 29737509 )
2018
6
Raman Spectroscopy for Inverted Papilloma: A Proof-of-Concept Study. ( 29763337 )
2018
7
Use of intraoperative negative margins reduces inverted papilloma recurrence. ( 29336292 )
2018
8
Human papillomavirus: An unlikely etiologic factor in sinonasal inverted papilloma. ( 29668071 )
2018
9
Analysis of miRNA expression profiling identifies miR-214-3p as a novel biomarker in sinonasal inverted papilloma. ( 29952653 )
2018
10
Benign inverted papilloma at bladder neck causing acute urinary retention. ( 29942474 )
2018
11
Survivin and cortactin expression in sinonasal schneiderian (inverted) papilloma and associated carcinoma. ( 29644904 )
2018
12
Endoscopic management of maxillary sinus inverted papilloma attachment sites to minimize disease recurrence. ( 29618385 )
2018
13
A Case of Inverted Papilloma of The Mastoid Cavity After Cholesteatoma Surgery. ( 29764790 )
2018
14
Management of maxillary sinus inverted papilloma via endoscopic partial medial maxillectomy with an inferior turbinate reversing approach. ( 28936551 )
2017
15
Long-term follow-up of a patient with malignant transformation of inverted papilloma into sinonasal undifferentiated carcinoma. ( 29070275 )
2017
16
Surgical management of inverted papilloma; a single-center analysis of 247 patients with long follow-up. ( 29262865 )
2017
17
Association of Krouse Classification for Sinonasal Inverted Papilloma With Recurrence: A Systematic Review and Meta-analysis. ( 28973390 )
2017
18
The analysis of expression of p16 protein in group of 53 patients treated for sinonasal inverted papilloma. ( 28479047 )
2017
19
Malignant transformation of nasal inverted papilloma into sarcomatoid carcinoma. ( 29512804 )
2017
20
Bone involvement: Histopathological evidence for endoscopic management of sinonasal inverted papilloma. ( 28722237 )
2017
21
Management of inverted papilloma: review. ( 28179032 )
2017
22
"TuNa-saving" endoscopic medial maxillectomy: a surgical technique for maxillary inverted papilloma. ( 28374054 )
2017
23
Recurrence of Sinonasal Inverted Papilloma Following Surgical Approach: A Meta-Analysis. ( 28490410 )
2017
24
Etiology of sinonasal inverted papilloma: A narrative review. ( 29204580 )
2017
25
Risk Factors of Recurrence and Malignant Transformation of Sinonasal Inverted Papilloma. ( 29250552 )
2017
26
Dysphagia caused by an inverted papilloma. ( 29237672 )
2017
27
Sinonasal undifferentiated carcinoma originating from inverted papilloma: A case report. ( 29137081 )
2017
28
Inverted papilloma of middle ear and temporal bone. ( 28233515 )
2017
29
Sinonasal Inverted Papilloma: Risk Factors for Local Recurrence After Surgical Resection. ( 28421830 )
2017
30
Different characteristics of a single sinonasal inverted papilloma from sequential PET-CT: A case report. ( 29384975 )
2017
31
Multifocal sinonasal inverted papilloma with middle ear involvement. ( 28966465 )
2017
32
Expression pattern of estroprogestinic receptors in sinonasal inverted papilloma. ( 28473663 )
2017
33
Endoscopic surgery of a sinonasal inverted papilloma: Surgical strategy, follow-up, and recurrence rate. ( 28234155 )
2017
34
Postoperative long-term morbidity of extended endoscopic maxillectomy for inverted papilloma. ( 28687815 )
2017
35
Ossifying inverted papilloma and ossifying polypA of the sinonasal tract: comparison ofA CTA andA MRI features. ( 27773333 )
2017
36
The clinical behavior of sinonasal inverted papilloma with cellular dysplasia: case series and review of the literature. ( 28597339 )
2017
37
The rapid change in sinonasal inverted papilloma incidence - the epidemiological analysis. ( 28485293 )
2017
38
Complete response of skull base inverted papilloma to chemotherapy: Case report. ( 28583236 )
2017
39
Outcomes of sinonasal squamous cell carcinoma with and without association of inverted papilloma: A multi-institutional analysis. ( 28859706 )
2017
40
Role of the Akt/mTOR signaling pathway in human papillomavirus-associated nasal and sinonasal inverted papilloma. ( 29040365 )
2017
41
Co-existence of mucin-producing urothelial-type adenocarcinoma of the prostate and inverted papilloma of the bladder. ( 28947891 )
2017
42
Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma. ( 28693263 )
2017
43
MRI-Based Texture Analysis to Differentiate Sinonasal Squamous Cell Carcinoma from Inverted Papilloma. ( 28255033 )
2017
44
Malignant transformation of sinonasal inverted papilloma and related genetic alterations: a systematic review. ( 28432463 )
2017
45
Survival outcomes after endoscopic resection for sinonasal squamous cell carcinoma arising on inverted papilloma. ( 27152722 )
2016
46
Removal of inverted papilloma from the frontal recess: how we do it. ( 26860209 )
2016
47
Inverted papilloma: The stubbornly persistent tumor of the sinonasal cavity. ( 26980387 )
2016
48
Endoscopic surgical management of sinonasal inverted papilloma extending to frontal sinuses. ( 28485285 )
2016
49
Is radical surgery of an inverted papilloma of the maxillary sinus obsolete? a case report. ( 27906054 )
2016
50
The prevalence of human papillomavirus infection in Iranian patients with sinonasal inverted papilloma. ( 26782082 )
2016

Variations for Inverted Papilloma

Cosmic variations for Inverted Papilloma:

9
(show all 17)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM496 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 11:533875-533875 16
2 COSM29440 FGFR3 urinary tract,bladder,papilloma,inverted c.1957A>C p.N653H 4:1806171-1806171 16
3 COSM29438 FGFR3 urinary tract,bladder,papilloma,inverted c.1921G>A p.D641N 4:1806135-1806135 16
4 COSM29432 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259L 4:1801870-1801870 16
5 COSM29431 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 16
6 COSM29434 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 16
7 COSM29437 FGFR3 urinary tract,bladder,papilloma,inverted c.1881G>T p.E627D 4:1806095-1806095 16
8 COSM29439 FGFR3 urinary tract,bladder,papilloma,inverted c.1927C>G p.H643D 4:1806141-1806141 16
9 COSM29436 FGFR3 urinary tract,bladder,papilloma,inverted c.1236C>T p.H412H 4:1804490-1804490 16
10 COSM715 FGFR3 urinary tract,NS,papilloma,inverted c.746C>G p.S249C 4:1801841-1801841 15
11 COSM10742 TP53 urinary tract,bladder,papilloma,NS c.578A>G p.H193R 17:7674953-7674953 9
12 COSM43814 TP53 urinary tract,bladder,papilloma,NS c.587G>C p.R196P 17:7674944-7674944 9
13 COSM43749 TP53 urinary tract,bladder,papilloma,NS c.595G>A p.G199R 17:7674936-7674936 9
14 COSM10801 TP53 urinary tract,bladder,papilloma,NS c.404G>A p.C135Y 17:7675208-7675208 9
15 COSM44602 TP53 urinary tract,bladder,papilloma,NS c.562C>G p.L188V 17:7674969-7674969 9
16 COSM714 FGFR3 urinary tract,bladder,papilloma,NS c.742C>T p.R248C 4:1801837-1801837 9
17 COSM718 FGFR3 urinary tract,bladder,papilloma,NS c.1118A>G p.Y373C 4:1804372-1804372 9

Expression for Inverted Papilloma

Search GEO for disease gene expression data for Inverted Papilloma.

Pathways for Inverted Papilloma

Pathways related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 CDKN2A PCNA TP53
2 11.73 CDKN2A MKI67 PCNA TP53
3 11.36 CDKN2A PCNA TP53
4 11.33 CDKN2A MSX2 PCNA TP53
5 10.94 PCNA TP53
6 10.91 CDKN2A TP53
7 10.83 PCNA TP53
8 10.66 CDKN2A TP53
9
Show member pathways
10.6 CDKN2A TP53

GO Terms for Inverted Papilloma

Cellular components related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.61 CDKN2A KRT13 KRT7 MKI67 MSX2 MT2A
2 intermediate filament GO:0005882 9.33 KRT13 KRT20 KRT7
3 replication fork GO:0005657 8.62 PCNA TP53

Biological processes related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.33 KRT13 KRT20 KRT7
2 replicative senescence GO:0090399 8.96 CDKN2A TP53
3 cornification GO:0070268 8.8 KRT13 KRT20 KRT7

Molecular functions related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.96 CDKN2A TP53
2 histone acetyltransferase binding GO:0035035 8.62 PCNA TP53

Sources for Inverted Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....